Drugs in Dev. Hepatology (Liver, Pancreatic, Gall Bladder)
Preclinical
South Korea 
Lead Product(s) : OLX702A
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OliX Pharmaceuticals Announces Positive Preclinical Data in NASH Non-human Primate Models
Details : The OLX702A program is based on compelling human genetic evidence which suggests that knockdown of this target may reduce liver fat, inflammation, and fibrosis and protect against liver-related mortality.
Product Name : OLX702A
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 11, 2022
Lead Product(s) : OLX702A
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OLX702A
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Olyx to Present Liver Disease Treatment and Base Technology at OTS Conference in 2021
Details : OLX702A, an investigational RNAi therapeutic for the treatment of nonalcoholic steatohepatitis (NASH). OliX will also present its pipeline OLX101A for hypertrophic scars, OLX104C for hair loss, OLX301A/D for age-related macular degeneration and subretina...
Product Name : OLX702A
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 27, 2021
Lead Product(s) : OLX702A
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LB-P8
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Mayo Clinic
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LISCure Biosciences How License Agreement ,Stock Purchase Agreement Mayo Clinic
Details : LISCure Biosciences will receive Mayo Clinic's know-how to establish a new drug, LB-P8, development of NASH program. As part of the agreement, Mayo Clinic will become a shareholder in LISCure, the first Korean biotech company receiving equity investment...
Product Name : LB-P8
Product Type : Microorganism
Upfront Cash : Undisclosed
July 27, 2021
Lead Product(s) : LB-P8
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Mayo Clinic
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : LB-P8
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $21.0 million
Deal Type : Series B Financing
LISCure Biosciences Successfully Raises $21 million in Series B Funding
Details : LISCure is developing the world's first microbiome-based NASH(non-alcoholic steatohepatitis) treatment, LB-P8, as well as the rheumatoid arthritis treatment, LB-P6, for global clinical trials.
Product Name : LB-P8
Product Type : Microorganism
Upfront Cash : Undisclosed
February 26, 2021
Lead Product(s) : LB-P8
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $21.0 million
Deal Type : Series B Financing
Reset All
